Physician profile
Tiffany James Ormand
NPI 1891366241
$1,667.33
in general payments reported to CMS, 2019-2025
8 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.15 · 2022: $439 · 2023: $415 · 2024: $344 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $503.52 | 2022-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $286.69 | 2022-2023 | Jakafi |
| Janssen Biotech, INC. | $270.15 | 2021-2025 | Darzalex, Carvykti, Rybrevant |
| Daiichi Sankyo INC. | $192.60 | 2022-2024 | Injectafer |
| Gilead Sciences, INC. | $189.76 | 2022-2023 | Trodelvy |
| Exelixis INC. | $105.08 | 2025 | Cabometyx |
| Beone Medicines USA, INC. | $102.42 | 2025 | Brukinsa |
| Argenx US, INC. | $17.11 | 2024 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Ormand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.